Circassia Pharmaceuticals PLC (LON:CIR) has been assigned a consensus rating of “Buy” from the six analysts that are covering the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is GBX 145 ($1.79).
Several research analysts have commented on the stock. Royal Bank Of Canada cut shares of Circassia Pharmaceuticals PLC to a “sector performer” rating and decreased their target price for the stock from GBX 430 ($5.32) to GBX 105 ($1.30) in a report on Tuesday, June 21st. Stifel Nicolaus restated a “buy” rating and set a GBX 375 ($4.64) price target on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Barclays PLC started coverage on shares of Circassia Pharmaceuticals PLC in a report on Tuesday, June 21st. They set an “overweight” rating and a GBX 170 ($2.10) price target for the company. Numis Securities Ltd restated an “under review” rating on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Finally, Peel Hunt cut shares of Circassia Pharmaceuticals PLC to an “add” rating and decreased their price target for the stock from GBX 509 ($6.30) to GBX 160 ($1.98) in a report on Tuesday, June 21st.
Circassia Pharmaceuticals PLC (LON:CIR) traded down 0.80% during midday trading on Wednesday, reaching GBX 93.00. 250,260 shares of the company were exchanged. Circassia Pharmaceuticals PLC has a one year low of GBX 81.05 and a one year high of GBX 322.90. The firm’s market cap is GBX 264.95 million. The firm’s 50-day moving average is GBX 94.21 and its 200-day moving average is GBX 168.19.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.